[HTML][HTML] Targeting macrophages in hematological malignancies: recent advances and future directions
Emerging evidence indicates that the detection and clearance of cancer cells via
phagocytosis induced by innate immune checkpoints play significant roles in tumor …
phagocytosis induced by innate immune checkpoints play significant roles in tumor …
[HTML][HTML] Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies
MP Chao, CH Takimoto, DD Feng, K McKenna… - Frontiers in …, 2020 - frontiersin.org
In recent years, immunotherapies have been clinically investigated in AML and other
myeloid malignancies. While most of these are focused on stimulating the adaptive immune …
myeloid malignancies. While most of these are focused on stimulating the adaptive immune …
[HTML][HTML] Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
SIRPα–CD47 immune checkpoint blockade in anticancer therapy
A Veillette, J Chen - Trends in immunology, 2018 - cell.com
Inhibitory immune checkpoint blockade has been one of the most significant advances in
anticancer therapy of the past decade. Research so far has largely focused on improving …
anticancer therapy of the past decade. Research so far has largely focused on improving …
[HTML][HTML] Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
TC Kuo, A Chen, O Harrabi, JT Sockolosky… - Journal of Hematology & …, 2020 - Springer
Background Signal regulatory protein α (SIRPα) is a myeloid-lineage inhibitory receptor that
restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of …
restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of …
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory
protein alpha (SIRPα) on a macrophage and CD47 on all types of cells–ranging from blood …
protein alpha (SIRPα) on a macrophage and CD47 on all types of cells–ranging from blood …
Phagocytosis checkpoints as new targets for cancer immunotherapy
Cancer immunotherapies targeting adaptive immune checkpoints have substantially
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …
improved patient outcomes across multiple metastatic and treatment-refractory cancer types …
Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer
N Gül, M van Egmond - Cancer research, 2015 - AACR
Nowadays, it is impossible to imagine modern cancer treatment without targeted therapies,
such as mAbs, that bind to tumor-associated antigens. Subsequently, mAbs can use a wide …
such as mAbs, that bind to tumor-associated antigens. Subsequently, mAbs can use a wide …
Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression
Tumor-associated macrophages (TAMs) are often the most abundant immune cells in the
tumor microenvironment (TME). Strategies targeting TAMs to enable tumor cell killing …
tumor microenvironment (TME). Strategies targeting TAMs to enable tumor cell killing …
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
MP Chao, IL Weissman, R Majeti - Current opinion in immunology, 2012 - Elsevier
Multiple lines of investigation have demonstrated that the immune system plays an important
role in preventing tumor initiation and controlling tumor growth. Accordingly, many cancers …
role in preventing tumor initiation and controlling tumor growth. Accordingly, many cancers …